Symtuza

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Symtuza is used to treat human immunodeficiency virus type 1 (HIV-1) infection in adults. Do not run out of Symtuza; even short delays in treatment can make HIV more difficult to treat.

Symtuza Overview

Reviewed: July 18, 2018
Updated: 

Symtuza is a prescription medication used to treat HIV-1 infection in adults who meet certain requirements.

It is a single product containing 4 medications: darunavir, cobicistat, emtricitabine, and tenofovir.

Darunavir, a protease inhibitor, along with emtricitabine and tenofovir, both nucleoside reverse transcriptase inhibitors (NRTIs), all work by decreasing the amount of HIV in the blood. Cobicistat is an inhibitor of an enzyme called CYP3A and works by increasing the amount of darunavir in the body and allowing it to have a greater effect.

This medication comes in tablet form and is taken once daily at the same time everyday, with food.

Common side effects include diarrhea, rash, and nausea.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Symtuza Drug Class

Back to Top

Symtuza FDA Warning

Back to Top

WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B

Severe acute exacerbations of hepatitis B (HBV) have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF), and may occur with discontinuation of Symtuza. Closely monitor hepatic function with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue Symtuza. If appropriate, anti-hepatitis B therapy may be warranted.